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Pancreatic ductal adenocarcinoma is the only cancer for which deaths are predicted
to increase in 2014 and beyond. Combined radiochemotherapy protocols using gem-
citabine and hypofractionated X-rays are ongoing in several clinical trials. Recent results
indicate that charged particle therapy substantially increases local control of resectable
and unresectable pancreas cancer, as predicted from previous radiobiology studies
considering the high tumor hypoxia. Combination with chemotherapy improves the overall
survival (OS). We compared published data on X-ray and charged particle clinical results
with or without adjuvant chemotherapy calculating the biological effective dose. We show
that chemoradiotherapy with protons or carbon ions results in 1 year OS significantly
higher than those obtained with other treatment schedules. Further hypofractionation
using charged particles may result in improved local control and survival. A comparative
clinical trial using the standard X-ray scheme vs. the best current standard with carbon
ions is crucial and may open new opportunities for this deadly disease.
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Introduction
Pancreatic cancer (PC), usually ductal adenocarcinoma, is the fourth cause of cancer-related death
in USA (1) and the only cancer for which deaths are predicted to increase in Europe for both men
and women in 2015 (2). Even after surgery, the mortality from PC is very high. Radiotherapy is used
for radical treatment in locally advanced unresectable tumors (LAUPC), generally in combination
with chemotherapy, or prior to surgery for potentially resectable malignancies. However, prognosis
remains very poor, with <5% of patients surviving for 5 years after diagnosis (3). This makes PC
a priority for finding betterways to control it and better treatments. Early tumors usually do not cause
symptoms, so that the disease is typically not diagnosed until it has spread beyond the pancreas itself,
either with distal metastasis or with infiltration in the neuroplexus. This is one of the reasons for the
poor survival rate. Moreover, PC is very hypoxic (4), which makes it radioresistant and promotes
epithelial–mesenchymal transition; is resistant to apoptosis; and presents a dense tumor stroma,
which acts as a barrier against immune cells, preventing immune suppression (5).
Radiobiology studies suggest that charged particle therapy (CPT) using protons or carbon
ions is more effective for treatment of PC than X-rays. In fact, accelerated ions have a reduced
oxygen enhancement ratio (OER), and are therefore exquisitely effective against hypoxic tumors
(6). Moreover, high doses of densely ionizing radiation elicit a strong immune response, which
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FIGURE 1 | Diagram summarizing the selection criteria of the studies included in the analysis.
can be exploited to destroy not only the primary tumor but also
distal metastasis (7). Carbon ion radiotherapy (CIRT) is currently
performed in only two centers in Europe (HIT in Germany and
CNAO in Italy) and none inUSA (wheremany centers use protons
only for CPT), but much more experience has been accumu-
lated in Asia, especially at the National Institute for Radiological
Sciences (NIRS) in Chiba, Japan. A recent external review of
20 years of CIRT at NIRS highlighted treatment of PC as the most
promising application of CIRT, with results clearly superior to any
other treatment modalities, especially for LAUPC (8).
Based on these very promising preliminary Japanese results,
the US National Cancer Institute (NCI), in his efforts to promote
CIRT in USA, issued a solicitation for a prospective randomized
phase-III trial comparing CIRT to X-ray therapy for LAUPC in
combination with chemotherapy, having survival as main end-
point1. This trial may provide the first evidence of a superiority
of CIRT in a common and deadly cancer. Planning of the trial is
complicated by the many different variables – not only radiation
quality but also chemotherapy regime, fractionation, and treat-
ment plan. Here, we review all the current results in treatment of
LAUPCanduse amathematicalmodel to describe the dependence
on survival on the biological effective dose (BED) with X-rays and
CPT in combination with chemotherapy.
1Solicitation number BAA-N01CM51007-51 (April 17, 2015) available online
through FedBizOpps at http://www.fbo.gov
Materials and Methods
Data Collection
We searched the literature for all data available on radiotherapy,
chemotherapy, and combined treatments. The research criteria
and outcomes are summarized in the diagram shown in Figure 1.
The patient populations generally consist of adults with adeno-
carcinoma histology, locally advanced tumor presentation, and
generally tumors not in direct contact to duodenum and stom-
ach. Radiotherapy included conformal radiotherapy (3DCRT),
intensity-modulated radiation therapy (IMRT), stereotactic body
radiotherapy (SBRT), protontherapy, and CIRT. Data from CIRT
are limited to the NIRS experience and include data as yet only
published in the institute annual report and in a recent book (9).
Adjuvant, neo-adjuvant, or concomitant chemotherapies were all
included in the search, using different drugs. Our data collection
was compared with a recent meta-analysis of radiochemotherapy
in LAUPC (10), and has been updated on April 2015.
Modeling
To compare the largely variable fractionation and chemotherapy
schedules reported in the literature, we used the common quan-
tity of BED (11), which has been extended to chemotherapy to
quantify the effect of the drug in terms of radiation-equivalent
dose (12). Because many published papers have short follow-up,
and not all endpoints are reported, we concentrated on the 1-year
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overall survival (OS). We assumed that the overall 1-year survival
probability OS is a combination of the survival probability follow-
ing the radiation (RS) and chemotherapy (CS) treatment, i.e.,
OS = CS+ RS (1  CS) (1)
Equation 1 implies a purely additive effect of chemotherapy and
radiotherapy in the treatment of LAUPC. The dose–response
for the OS probability can be expressed with the same functions
used for the tumor control probability: Poisson, logistic, or probit
models (13).We elected to use the logistic function, which is based
on the linear-quadratic model, following the recent model of
chemoradiation treatment in bladder cancer (14). Thus, we wrote:
RS = 1
1+ exp

4γ50

1  BEDD50
 (2)
where γ50 is the normalized dose-response gradient and D50 the
BED corresponding to a survival in a radiotherapy only treatment
of 50% at 1 year.
Combining Eqs 1 and 2, we finally obtain
OS =
1+ CS  exp

4γ50

1  BEDD50

1+ exp

4γ50

1  BEDD50
 (3)
In a recent analysis of chemoradiation therapy in LAUPC,Moraru
et al. (15) used a radiosensitization factor in the BED formula
and fitted the LAUPC 1 year OS data with a modified linear-
quadratic formula. In general, it is very hard to distinguish addi-
tive from synergistic model in chemoradiation data (16). In vitro
experiments can provide some information, but do not necessarily
reflect the complex in vivo microenvironment. Some chemother-
apy drugs used for LAUPC treatment apparently sensitize cell
cultures to X-rays (17, 18), but simple additive effects are observed
when the drugs are given in vitro concomitantly to charged parti-
cles (19, 20). Moreover, in many clinical protocols, chemotherapy
is given as adjuvant or neo-adjuvant, and even when concomi-
tant is often continued after the radiotherapy cycle. We therefore
assumed, in our analysis, that the simple additive model of Eqs 1
and 3.
The BED was calculated using the Fowler formula (11):
BED = nd

1+ d
α=β

  ln(2)
α
 TTd (4)
with:
– n: number of fractions
– d: dose/fraction
– T: overall treatment time
– α= 0.393Gy 1, β= 0.058Gy 2, α/β= 6.77Gy (21)
– Td: tumor doubling time, fixed to 42 days (15).
The dose/fraction d was given in Gy for X-ray data,
and Gy(RBE) (or GyE) for CPT. For protontherapy,
1Gy(RBE)= 1.1Gy (22). In CIRT, Gy(RBE) was calculated
according to the NIRS model (23), whose results can be different,
depending on the dose and target size, from those that would
be obtained using the LEM model (24), implemented in the
European CIRT facilities.
Fitting
Clinical data extracted from the published papers were weighted
with a vertical error bar, given by the SD of the OS using Poisson
statistics:
OS1 Year =
ns
ntot

pns
ntot
(5)
where ns and ntot indicate the number of surviving patients at
1 year and the total number of patients included in the study,
respectively. When possible, a horizontal error bar was also
included, corresponding to the range of the doses used. A first
weighed fit of the radiotherapy-alone data was performed using
Eq. 2 to estimate the two parameters γ50 and D50. The chemora-
diation data were then fitted using Eq. 3 having CS as only fitting
parameter: γ50 and D50 were indeed taken from the radiotherapy
fit. Many different chemotherapy drugs were used in old and new
studies. Gemcitabine is one of the most successful and currently
adopted, also in the CIRT trials. We have therefore divided the
data into gemcitabine only, other drugs, and gemcitabine plus
other drugs. Overall, no statistically significant differences were
noted among the three groups. We have therefore fitted the data
together, even if we plotted the points in different colors. Finally,
for fitting the CPT data, we expressed the BED in Gy(RBE) as
described above, and used Eq. 3 with a fixed CS and γ50 taken
from the fit of the chemoradiation data with X-rays. In fact, we
assume that CPT has an impact on the D50 due to the putative
improved dose distribution in the target and to the radiobiological
properties beyond the calculated RBE used in the Gy(RBE).
Results
Single Treatment Data
Chemoradiation is generally considered the best standard of cure
for LAUPC. For this reason, only a few studies are available with
radiotherapy alone, and some of them are old (Table 1). Some
recent studies using SBRT have been excluded. An initial trial in
TABLE 1 | Clinical data for treatment of LAUPC using X-ray radiotherapy alone.
Reference Year Total dose (Gy) Fractions Sample size 1 year OS 2years OS Median OS
Moertel et al. (38) 1969 35–40 20 28 7% N/A N/A
Moertel et al. (39) 1981 60 30 25 10% N/A 5.3months
Ceha et al. (40) 2000 70–72 35–36 44 39% N/A 10months
Cohen et al. (41) 2005 59.4 33 49 20% N/A 7.1months
Wang et al. (42) 2015 46 23 14 35% 14% 7.4months
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Stanford using high-dose (25Gy) single-fraction reports a 100%
survival at 1 year, but this was limited to six patients (25). Later
results from Stanford using SBRT are included in Table 2. On the
other hand, a Danish study using 45Gy in three fractions gave
very low OS and high toxicity (26). This study was also excluded
in our analysis, because these poor outcomes were likely a result
of inaccurate positioning, lack of effective motion management
techniques, and lack of dose constraints for OARs (27).
The data are plotted in Figure 2, along with the fit using Eq.
2. Fitting parameters are reported in Table 2. The D50 = 107Gy
clearly shows how impractical is the treatment of LAUPC with X-
rays alone. For comparison, Dale et al. (16) estimated a BED at
50% complete response for bladder cancer of 54.4Gy. From the
analysis of the trials using chemotherapy alone (10), an average
1-year survival below 20% can be estimated.
Chemoradiation
Meta-analysis of the clinical data has already shown an
advantage in chemoradiation compared to radiotherapy or
chemotherapy alone (10). Most clinical trials for LAUPC resort
to chemoradiation protocols. Gemcitabine (Table 3) is often
regarded as the standard treatment. Several other drugs, such as
capecitabine, fluorouracil (5-FU), cisplatin, docetaxel, cetuximab,
and fluoropyrimidine prodrug S-1, have been used in the past
or in new trials (Table 4), and often combination of gemcitabine
and any of the other drugs (Table 5) are applied. The standard
FIGURE 2 | Fit of the clinical data for treatment of LAUPC with X-ray
radiotherapy alone. Studies are listed in Table 1. BED is calculated by
Eq. 4. Fitting was performed by Eq. 2 and fitting parameters are in Table 3.
TABLE 2 | Clinical data for treatment of LAUPC using X-ray therapy plus gemcitabine.
Reference Year Total
dose (Gy)
Fractions Chemotherapy Sample
size
1 year
OS
2years
OS
Median OS
(months)
Wolff et al. (43) 2001 30 10 Gem, 350–500mg/m2/week for 7weeks 18 66% N/A 6
Epelbaum et al. (44) 2002 50.4 28 Gem, 1000mg/m2 weekly before and after RT,
Gem 400mg/m2 weekly during RT
20 30% N/A N/A
Joensuu et al. (45) 2004 50.4 28 Gem, 20/50/100mg/m2 twice weekly before RT 28 55% N/A 25
Okusaka et al. (46) 2004 50.4 28 Gem, 250mg/m2 weekly+maintenance
1000mg/m2 weekly for 3weeks every 4weeks
38 28% 23% 9.5
Murphy et al. (47) 2007 36 15 Gem, 1000mg/m2 on days 1, 8, and 15 74 46% 13% 11.2
Small et al. (48) 2008 36 15 Gem, 1000mg/m2 2–3 times/week before, during,
and after RT treatment
14 47% N/A N/A
Igarashi et al. (49) 2008 40–50.4 20–28 Gem, 40mg/m2 twice/week+maintenance
1000mg/m2 for 3weeks
15 60% N/A 15
Schnellenberg et al. (50) 2008 25 1 Gem, 1000mg/m2 weekly for 3weeks before
RT+maintenance weekly
16 50% N/A 11.4
Polistina et al. (51) 2010 30 3 Gem, 1000mg/m2 weekly for 6weeks before
RT+maintenance weekly
23 39.1% 0% 10.6
Loehrer et al. (52) 2011 50.4 28 Gem, 600mg/m2 weekly before and during RT 34 50% 12% 11.1
Schnellenberg et al. (53) 2011 25 1 Gem, 1000mg/m2 weekly before and after RT 20 50% 20% 11.8
Cardenes et al. (54) 2011 50.4 28 Gem, 600mg/m2 weekly before and during
RT+maintenance 1000mg/m2 weekly
28 30% 11% 10.3
Shibuya et al. (55) 2011 54 30 Gem, 250mg/m2 weekly during RT+maintenance
1000mg/m2 every 4weeks (discretional)
21 74% N/A 16.6
Mahadevan et al. (56) 2011 24–36 3 Gem, 1000mg/m2 weekly before, during, and after
RT (at least 6 cycles)
39 72% 33% 20
Huang et al. (57) 2011 50.4–63 28–35 Gem, 1000mg/m2 weekly during
RT+ induction/adjuvant (discretional)
55 51% N/A 12.5
Mukherjee et al. (58) 2013 50.4 28 Gem, induction 300mg/m2+ concurrent
1000mg/m2
38 64.2% N/A 13.4
Gurka et al. (59) 2013 25 5 Gem, 1000mg/m2 weekly before and after RT 10 50% N/A 12.2
Herman et al. (60) 2014 33 5 Gem, 1000mg/m2 weekly before and after RT 49 59% 18% 13.9
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TABLE 3 | Fitting parameters calculated using the Eqs 2 or 3.
Dataset Table γ50 D50 [Gy or Gy(RBE)] Chemotherapy survival rate (CS) Figure
Radiotherapy (X-rays) alone 1 1.20.5 10716 N/A 2
Radiotherapy (X-rays)+ gemcitabine 2 1.2 (fixed) 107 (fixed) 0.390.03 3
Radiotherapy (X-rays)+ chemotherapy other than gemcitabine 4 1.2 (fixed) 107 (fixed) 0.320.02 3
Radiotherapy (X-rays)+ chemotherapy (all protocols combined) 3–5 1.2 (fixed) 107 (fixed) 0.360.01 4
CPT+ chemotherapy 6 1.2 (fixed) 759 0.36 (fixed) 5
X-ray course is 50.4Gy in 1.8Gy/fraction, giving a BED of 63Gy.
We did not find significant differences in the groups treated with
different drugs, considering the very high scatter of the data
also due to the completely different protocols adopted. Figure 3
shows, for example, a comparison of the data in Tables 3 and 4,
pointing only to a slight trend for better results in protocols using
gemcitabine compared to other drugs. Figure 4 shows the fit of all
the data compared to X-rays alone. Having fixed the γ50 and D50
parameters, we estimated the only parameter CS= 0.36 0.01
(Table 2). The radiation dose corresponding to this survival
probability RS=CS can be estimated by Eq. 2 as
BED (chemo – equivalent)=D50

1  ln
1 RS
RS
4γ50

(6)
leading to a chemo-equivalent dose of 94Gy. This high value
underlines the large improvement that chemotherapy gives on the
survival of LAUPC patients. Dale and co-workers (16) estimated
43.6Gy for the BED chemo-equivalent in bladder cancer. They
also demonstrated that the chemo-equivalent dose is not a con-
stant andwill be of coursemuch lower if we calculate it for a higher
survival level.
Charged Particle Therapy
Although only a few studies are available with CPT, the data in
Table 6 show that they are the best current options for LAUPC.
A 2-year survival rate around 50% was reached with protons
(28) or C-ions (9) in combination with gemcitabine, a value far
exceeding any other chemoradiation trial using X-rays and any
cocktail of drugs. The data with CIRT alone (no chemotherapy)
are clearly superior to those with X-rays alone and comparable to
the results with chemoradiation at the same X-rays BED. The best
1-year OSs for combined chemotherapy (gemcitabine) and CPT
are those fromHyogo (28) using protons up to 70.2Gy(RBE) in 26
fractions, but they came at a cost of grade 3–5 toxicity in 10%of the
patients, especially gastric ulcer and hemorrhage. CIRT toxicity
was much more mild, with 17% of the patients experiencing
grade 3 GI toxicity, in the form of appetite loss. Low toxicity
was observed for the duodenum, both for protons and 12C-ions.
The fit of the chemoradiation with CPT, using the same CS and
γ50 parameters calculated for X-rays+ chemotherapy, is shown in
Figure 5. This fit assumes that CPT does not change the effect of
the chemotherapy compared to X-rays, but results in a lower D50
due to biological and/or physical improvements compared to X-
rays. Should these improvements be already included in the RBE
model used to calculate the equivalent dose inGy(RBE),we should
see the same effect at the same BED [see Ref. (23) for CIRT in
Japan; RBE= 1.1 for protons]. Instead, the best fit is reduced to
D50 = 75 9Gy(RBE) for CPT (Table 2). This 50% improvement
is caused either by a better physics, enabling treatment of infil-
trations in the neuroplexus, or to a better biology, especially to a
reduced OER (6) or to a stronger immune response (7) using CPT
compared to X-rays.
Discussion
The large interest for the use of CPT in LAUPC comes from
the exceptional clinical results (8), supported by our clinical data
analysis inFigure 5. These results reflect the biological rationale of
reduced OER for high-LET radiation and possible dose escalation
with limited side effects exploiting the Bragg peak. The high GI
toxicity observed in the Hyogo trial (28) seems to set a threshold
at a BED around 100Gy(RBE). The question is whether the same
threshold applies to CIRT, where the sharper dose edges of the
treatment plan may reduce the exposure of the critical organs
compared to protons, whose lateral scattering is much higher
than for heavy ions (6). An example of a treatment plan of a
pancreatic head cancer with carbon ions is shown in Figure 6. It is
possible to give a high-dose against tumor and neuroplexus with
acceptable doses to stomach or duodenum. The dose distribu-
tion can further improve using raster scanning instead of passive
modulation, as shown in Figure 7. The new NIRS facility is now
equipped with raster scanning, and so are the HIT and CNAO
facilities now treating the first LAUPCpatientswithC-ions.Under
these optimal conditions, it appears feasible to exceed a BED of
100Gy(RBE) with acceptable toxicities.
Modeling chemotherapy in terms of equivalent radiation dose
is an effective method to predict outcomes of dose-escalation
trials (12, 16). The large scatter in the chemoradiation data leads,
however, to a poor goodness-of-fit in Figures 3 and 4. This is due
in part to the many different protocols used in chemotherapy for
LAUPC, and to inclusion of data published in over 30 years using
very different methods both for drug and radiation delivery. In
this paper, we have decided to analyze all the data available in the
literature, without including the treatment year as a function in the
model. We have also assumed no synergistic interaction between
chemicals and radiation. Finally, Eq. 4 should bemodified for pro-
tons or carbon ions, where α/β is higher than for X-rays leading to
a lower dependence on fractionation. Due to the lack of sufficient
information leading to an educated guess for other parameters and
models, we decided to stick to the conventional logistic function,
replacing Gy with Gy(RBE) in Table 6. The basic assumption
remains that a higher BED will result in a higher OS in LAUPC
patients, an assumption clearly supported by the analysis of the
several trials included in our data mining. Our analysis supports
the concept that a dose escalation will improve OS, and toxicity
is the limiting factor. In Table 7, we have calculated with the
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TABLE 4 | Clinical data for treatment of LAUPC using X-ray therapy plus chemotherapy, excluding the trials with gemcitabine.
Reference Year Total
dose (Gy)
Fractions Chemotherapy Sample
size
1 year
OS
2years
OS
Median OS
(months)
Moertel et al. (39) 1981 40 20 5-FU 500mg/m2 3days/week during RT,
maintenance 5-FU 500mg/m2 weekly
83 46% N/A 11.4
60 30 85 35% N/A 8.4
Wagener et al. (61) 1996 40 20 Epirubicin+Cisplatin+ 5-FU 53 49% N/A 10.8
Ishii et al. (62) 1997 50.4 28 5-FU 500mg/m2 3days/week during RT 20 41.8% N/A 10.3
Fisher et al. (63) 1999 45 25 5-FU 150–250mg/m2 continuous infusion
24 h/day during RT
25 32% N/A 9
Andre et al. (64) 2000 45 25 5-FU 375mg/m2+Cisplatin 15mg/m2 daily
during RT (first and last week)+maintenance
after RT
32 31% 12.5% 9
Boz et al. (65) 2001 59.4 33 5-FU 150–300mg/m2 continuous infusion
24 h/day during RT
42 30% N/A 9.1
Safran et al. (66) 2001 50.4 28 Paclitaxel 50mg/m2 weekly during RT 44 30% N/A 8
Li et al. (67) 2003 50.4–61.2 28–34 5-FU 500mg/m2 for 3 days every 2weeks during
RT, Gem 1000mg/m2 after RT
16 31% 0% 6.7
Morganti et al. (68) 2004 39.6–59.4 22–33 5-FU 1000mg/m2 during RT at days 1–4 and
21–24
50 31.3% N/A N/A
Cohen et al. (41) 2005 59.4 33 5-FU 1000mg/m2 at days 1–4 and
21–24+Mitomycin 10mg/m2 at day 2 during RT
55 31% N/A 8.4
Park et al. (69) 2006 20 10 5-FU 500mg/m2 for 3 days twice during RT with
2weeks break
56 37% 14.6% 10.4
Chauffert et al. (70) 2008 60 30 5-FU 300mg/m2 5days/week for
6weeks+Cisplatin 20mg/m2 5days/week on
weeks 1 and 5, maintenance Gem 1000mg/m2
weekly
59 32% N/A 8.6
Crane et al. (71) 2009 50.4 28 Capecitabine 825mg/m2 twice
daily+Bevacizumab 5mg/kg on days 1, 15, and
29; maintenance Gem 1000mg/m2
weekly+Bevacizumab 5mg/kg every 2weeks
82 47% N/A 11.9
Sudo et al. (72) 2011 50.4 28 S-1 80mg/m2 daily during and after RT 34 70.6% N/A 16.8
Oberic et al. (73) 2011 54 30 Docetaxel 20mg/m2 weekly+ 5-FU 200mg/m2
daily during RT
20 40% N/A 10
Brunner et al. (74) 2011 55.8 33 5-FU 1000mg/m2 on days 1–5 and
29–33+Mitomycin 10mg/m2 on days 1–29
during RT
35 40% N/A 9.7
Huang et al. (57) 2011 50.4–63 28–35 5-FU 200–300mg/m2 5days/week or 5-FU
500mg/m2 on days 1–3 and 29–31 or
capecitabine 1300–1600mg/m2 daily during RT
38 24% N/A 10.2
Malik et al. (75) 2012 50.4 28 5-FU based during RT* 84 52.6% N/A 10.9
Ikeda et al. (76) 2012 50.4 28 S-1 80mg/m2 twice daily during RT, maintenance
S-1 80mg/m2 daily after RT
60 72% N/A 16.2
Schinchi et al. (77) 2012 50 40 S-1 80mg/m2 twice daily during and after RT 50 62% 27% 14.3
Mukherjee et al.
(58)
2013 50.4 28 Capecitabine 830mg/m2 5days/week induction
and concurrent to RT
36 79.2% N/A 13.4
Herman et al. (78) 2013 50.4 28 5-FU 200mg/m2 daily during RT, maintenance
Gem 1000mg/m2 weekly
90 36.7% 10.3% 10
5-FU 200mg/m2 daily+ TNFerade weekly during
RT, maintenance Gem 1000mg/m2 weekly
187 41% 11.3% 10
Ducreaux et al. (79) 2014 54 30 Docetaxel 20mg/m2+Cisplatin 20mg/m2
weekly during RT
51 41% 31% 9.6
Rembielak et al.
(80)
2014 50.4 28 Cetuximab loading dose
400mg/m2+250mg/m2 weekly during RT
21 33% 11% 7.5
Kwak et al. (81) 2014 50.4 28 5-FU 600–1000mg/m2 during RT, maintenance
Gem 200mg/m2 weekly
34 40% 10% 9
*Limited information about chemotherapy.
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TABLE 5 | Clinical data for treatment of LAUPC using X-ray therapy plus a chemotherapy cocktail including gemcitabine.
Reference Year Total
dose (Gy)
Fractions Chemotherapy Sample
size
1 year
OS
2years
OS
Median
OS
Chung et al. (82) 2004 45 25 Gem 1000mg/m2 weekly+Doxifluoridine 600mg/m2 daily
during and after RT
22 50% N/A 12
Haddock et al. (83) 2007 45 25 Gem 30mg/m2+Cisplatin 10mg/m2 twice weekly during
first 3weeks of RT, Gem 1000mg/m2 weekly after RT
48 40% N/A 10.2
Hong et al. (84) 2008 45 25 Gem 1000mg/m2 weekly+Cisplatin 70mg/m2 two times
during RT, maintenance Gem 1000mg/m2
weekly+Cisplatin 70mg/m2 every 4weeks
38 63.3% 27.9% 16.7
Mamon et al. (85) 2011 50.4 28 Gem 200mg/m2 weekly+ 5-FU 200mg/m2 5days/week
during RT, maintenance Gem 1000mg/m2 weekly
78 51% N/A 12.2
Crane et al. (86) 2011 50.4 28 Gem 1000mg/m2+Oxaliplatin 100mg/m2 before
RT+Capecitabine 825mg/m2 twice daily on RT days,
cetuximab 500mg/m2 every 2weeks before and during RT
69 66% 25% 19.2
Brunner et al. (74) 2011 55.8 31 Gem 300mg/m2+Cisplatin 30mg/m2 weekly during RT 58 53% N/A 12.7
Ch’Ang et al. (87) 2011 50.4 28 Gem 800mg/m2+Oxaliplatin 85mg/m2+5-FU/Leucovorin
3000/150mg/m2 twice/week before RT, Gem 400mg/m2
weekly during RT
50 68% 20.6% 14.5
Tozzi et al. (88) 2013 45 6 Gem-based before RT 30 47% N/A 11
Ke et al. (89) 2014 50.4 28 Gem 1000mg/m2 weekly+S-1 40mg/m2 twice daily before
RT, S-1 80mg/m2 twice daily during RT, S-1 80mg/m2
twice daily 1month after RT
32 75% 34.4% 15.2
Wang et al. (42) 2015 46 23 Gem-based (sub-groups) 16 71.1% 40.6% 19.5
FIGURE 3 | One-year survival as a function of the BED for patients
undergoing X-ray radiotherapy plus gemcitabine (red symbols), or
other chemotherapy drugs (blue symbols). Data are reported in Tables 2
and 4. The lines show the result of the fit (Eq. 3), which was performed
assuming that γ50 and D50 are obtained by fitting the data in treatments using
radiotherapy only (Figure 1). The only free fitting parameter is the
chemotherapy survival CS (see Table 3). The results suggest that the final
outcome does not strongly depend on the specific chemotherapy treatment,
although some advantage seems to be associated to the use of gemcitabine.
logistic model (Eq. 3) the expected survival in hypofractionated
dose-escalation trials and compared with the standard chemora-
diation treatment and other schedules proposed for SBRT using
X-rays (15, 27). The standard at NIRS is 12 fractions in 3weeks,
and with the current maximum dose/fraction the OS at 1 year is
expected to improve from 40 to 70% compared to the standard X-
ray regime (50.4Gy in 28 fractions). Reaching 18 fractions with
the same dose/fraction, it could be possible to double the survival.
FIGURE 4 | One-year survival as a function of the BED for patients
undergoing X-ray radiotherapy alone (black symbols), or in
combination with any chemotherapy treatments. Details about
chemotherapy regimen are reported in Tables 4–6. The lines show the result
of the fit (black for radiotherapy-alone data, red for all chemotherapy data
pooled together), which was performed assuming that γ50 and D50 are
obtained by fitting RT-alone data. Fitting parameters with Eq. 3 are in Table 3.
Further hypofractionation, down to a single dose of 25Gy(RBE)
is very attractive in terms of expected survival, but raises concerns
for the GI toxicity. C-ions delivered by raster scanning should pro-
vide the optimal dose distributions (Figure 7) compared to CIRT
with passive scattering and protons, where the lateral scattering
unavoidably leads to a dose penumbra around the PTV. However,
for beam scanning, the issue of motionmitigationmust be tackled
very carefully, because of the known problem of the interplay.
Currently, NIRS is using respiratory gating to compensate espe-
cially the movements of stomach and duodenum in the PTV
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(Figure 8). A treatment with high number of fractions compen-
sates the interplay between beam scanning and organ motion, but
this compensation is lost in radiosurgery (29). In the treatment
of hepatocellular carcinoma with 12C-ions at the HIT facility
in Heidelberg, it has been shown that the simple increase from
1 to 4 fractions substantially improved the dose target coverage
and reduced overdosage (V107 from 32 to 4%) (30), this means
that keeping the hypofractionation schemes above 4 fractions,
major inhomogeneities should be avoided.Nevertheless, the range
FIGURE 5 | One-year survival as a function of the BED for patients
undergoing CPT with or without additional chemotherapy. Blue
symbols refer to patients receiving radiotherapy with C-ions without additional
chemotherapy. Green symbols refer to data obtained with proton (triangles)
and carbon ions (full squares) in combination with chemotherapy. Data are
given in Table 6. The green line shows the result of the fit of data for
chemotherapy combined with proton or carbon ions. The fit was performed
using γ50 and CS from X-ray+ chemotherapy data. The only free parameter is
therefore D50. The black and red lines show the results of the fit for X-rays
alone and X-rays plus chemotherapy, and are reported for comparison. Fitting
parameters are in Table 3.
uncertainties due to bowel movement, stomach peristalsis, and
breathing, have to be solved to reduce toxicity to the many crit-
ical organs surrounding the pancreas. Motion mitigation strategy
include respiratory gating or layer stacking boost irradiation, such
as used at NIRS for treating PC (31), and 4D optimization of the
plan based on 4DCT (32). Patients with tumors in a favorable
location, preferably>1 cm from the closest luminal organ, should
be selected for the dose escalation.
The solution of this problem is an important step to push
toward higher doses and fewer fractions thus leading to a
substantial improvement in survival can be expected using
chemoradiation protocols with CPT rather than X-rays. The first
FIGURE 6 | A typical treatment plan used at NIRS for a locally
advanced pancreatic head cancer. The beam is shaped with passive
modulation and four opposite fields are applied with respiratory gating. GTV
includes the primary tumor and lymph nodes involved.
CTV=PTV+ neuroplexus infiltration (periarterial area)+proximal lymph
nodes. PTV=CTV+5mm, excluding GI tract.
FIGURE 7 | Comparison of the current passive beam modulation
treatment plan with a spot scanning treatment plan for LAUPC. In the
right panel, the dose–volume histogram for different organs is shown for passive
modulation (dotted line) and raster scanning (solid line). Dose to the spinal cord
and kidney are highly reduced. Potential reduction is also clear for stomach and
duodenum, whose movements are, however, critical.
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TABLE 6 | Clinical data for treatment of LAUPC using CPT.
Reference Year Radiation
quality
Total dose
in Gy (RBE)
Fractions Chemotherapy Sample
size
1 year
OS
2years
OS
Median
OS
Terashima et al. (28) 2012 Protons 67.5 25 Gem, 800mg/m2/week for 3weeks 50 76.8% 50% N/A
Sachsman et al. (90) 2014 Protons 59.4 33 Capecitabine, 1000mg twice/day; 5 days/
week on radiation treatment days only
11 61% 31% 18.4
Yamada et al. (9) 2014 Carbon ions 38.4–43.2 12 – 19 36% 5% N/A
Gem 1000mg/m2/week for 3weeks 24 71% 21% N/A
45.6–52.8 12 – 27 47% 16% N/A
Gem 1000mg/m2/week for 3weeks 47 74% 54% N/A
TABLE 7 | Expected improvement in survival according to our model in chemoradiation trials using CPT.
Dose/fraction in
Gy or Gy(RBE)
Radiation
quality
Fractions Total dose in
Gy or Gy(RBE)
BED in
Gy or Gy(RBE)
Expected 1 year
survival rate
Comments
1.8 X-rays 28 50.4 62.9 42% Current standard fractionation scheme
2.25 X-rays 33 74.3 97.8 61% Proposed dose-escalation trial at Medical College of
Winsconsin (15)
6.6 X-rays 5 33 65.2 45% Standard for SBRT in adjuvant settings (27)
2.7 Protons 26 70.2 97.4 75% Maximum dose reached at Hyogo
4.6 C-ions 12 55.2 92.5 71% Maximum dose reached at NIRS
5.85 C-ions or
protons
12 70.2 130.6 82% Maximum total dose reached with protons in Hyogo using
the number of fraction from NIRS
25 C-ions or
protons
1 25 117.5 76% Maximum dose used in single-fraction X-ray radiosurgery
for LAUPC (27)
4.6 C-ions or
protons
18 82.8 138.6 84% Expected doubling of the OS with conventional X-ray
fractionation scheme, using the dose/fraction from NIRS
BED is calculated by Eq. 4. Expected 1 year survival is calculated using Eq. 3 and the parameters in Table 3.
FIGURE 8 | 4DCT analysis of the movement of the critical organs
during treatment of LAUPC at NIRS with C-ions. T0 is the peak inhalation
and T50 the peak exhalation phases. Stomach and duodenum move in and
out the PTV in the two phases.
clinical CIRT vs. IMRT trial for LAUPC should compare the stan-
dard chemoradiation treatment (Table 7, row 1), with the NIRS
most advanced protocol (Table 7, row 5). The additional advan-
tage of using the standard protocols is that at the dose/fraction
of 4.6Gy(RBE) reached in the escalation trial at NIRS, there is
practically no difference between the biological dose calculated
at NIRS and those predicted by LEM (24) and implemented in
European CIRT facilities. However, in a multi-centric trial, it will
be unavoidable to have different systems for dose delivery, motion
management, patient selection, etc. For instance, NIRS is using
passive modulation, CNAO raster scanning, and HIT can use the
gantry. Nevertheless, a comparative trial for LAUPC is absolutely
necessary to support the use of CIRT and to confirm the very
promising data in the phase I–II trials at NIRS (8). The lack
of comparative, phase-III clinical trials is generally considered
as a major hindrance to a more widespread use of CPT in the
clinics (33). A trial on LAUPC may definitely clarify the clinical
advantage of CPT in such a lethal tumor.
Apart from the international comparative trial, further devel-
opments of phase-II trials with CPT should point to two direc-
tions. First, several molecular markers, such as mutations in
SMAD4/DPC4, have been validated as prognostic factors in PCs
(34). Whole-genome sequencing and copy number variation
analysis suggest that PCs can be divided into four genetic subtypes,
with potential clinical utility (35). Trials with CPT combined
with molecular analysis of these genes are highly needed, because
CPT may elicit different molecular pathways than conventional
X-rays (36). Combined CIRT+ gemcitabine may be especially
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effective against pancreatic stem-like cells, as suggested by a recent
in vitro study (37), and hence, study of stem cells markers and
genetic pathways will be highly desirable. In addition, further
hypofractionation is desirable if the problems of the organ move-
ments are tackled as described above. For instance, the use of
12 fractions (such as done at NIRS) with the total dose used for
protons in Hyogo is expected to push the 1-year survival over 80%
(Table 7, row 6). A careful motion mitigation strategy should be
rapidly implemented to allow this further escalation.
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